18 min listen
Targeting a Natural Repair System to Restore Brain Health
FromThe Bio Report
ratings:
Length:
19 minutes
Released:
Feb 28, 2024
Format:
Podcast episode
Description
The HGF/MET neurotrophic system plays a critical role in the maintenance and repair of connections in the brain. Enhanced signaling along this pathway has the potential to reduce inflammation, slow neurodegeneration, and provide neuroprotection. Athira Pharma is pursuing small molecule drugs that target this pathway to address a range of neurodegenerative conditions. The company is currently conducting a phase 2/3 study of its lead therapeutic candidate, fosgonimeton, in mild-to-moderate Alzheimer’s disease. But the study comes after the experimental therapy failed to meet its primary endpoint in a phase 2 study in Alzheimer’s disease and a phase 2 study in Parkinson’s disease dementia and dementia with Lewy bodies. We spoke to Rachel Lenington, chief operating officer of Athira Pharma, about the case for targeting the HGF/MET neurotrophic system in neurodegenerative diseases, how its experimental therapy fosgonimeton works, and why its continuing to pursue the therapy despite earlier failures.
Released:
Feb 28, 2024
Format:
Podcast episode
Titles in the series (100)
The Power of IBM’s Watson Is Coming to an App Near You: IBM’s Watson Group recently announced an investment in Pathway Genomics, part of a $100 million initiative by the computing giant to spur innovation in entrepreneurial companies that seek to leverage its cognitive computing platform Watson. Pathway G... by The Bio Report